Chronic granulomatous disease (CGD) is a primary immunodisorder caused by impairment of the phagocyte NADPH-oxidase function. Despite improvements in treatment, cases of CGD have been associated with serious infection, episodes of surgery, and hospitalization [1] . Survival probability of CGD patients has improved over the decades, but infections are still a major cause of morbidity and mortality when treated conservatively [2] .
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Allogeneic hematopoietic stem cell transplantation (HSCT) is performed as a curative approach for CGD [3] . A recent survey revealed high rates of medical and social handicaps in non-transplanted cases reaching adulthood that suggest an extended indication of HSCT for CGD cases [4] . Myeloablative conditioning regimens have been used historically, and have achieved improved survival compared to cases without HSCT [5] . In this decade, reduced-intensity conditioning (RIC) regimens have been increasingly adopted to avoid transplantation-related morbidity and mortality. However, previous challenges of RIC regimens resulted in high risk of graft failure or mixed chimerism that could be associated with graft loss and other complications [6, 7] . Recently, a multicenter prospective clinical trial conducted by the European Bone Marrow Transplantation (EBMT) Group demonstrated that a targeted busulfan (BU)-based conditioning regimen for HSCT from HLA-matched donors (including HLA-9/10 matched donors) achieved a high rate (89%) of event-free survival with excellent donor chimerism and minimal toxicity [8] . However, further evidence is required to establish an optimal conditioning regimen in HSCT for CGD.
We conducted a prospective clinical trial, aiming to confirm the efficacy and safety of RIC with targeted BU in HSCT from unrelated donors, including HLA-mismatched donors. In our study, conditioning consisted of targeted BU, fludarabine (FLU), and anti-thymoglobulin (ATG). BU was NA not available a UPN 6 developed secondary graft failure at day 56 GVHD graft versus host disease, SOS sinusoidal obstruction syndrome administered intravenously four times daily from days -5 to -2. The dose of BU was adjusted based on results of pharmacokinetics of the test-dose [9] to target area-underthe-curve (AUC) values of 45-65 mg/L × h, equivalent to 55 to 75% of the full myeloablative cumulative AUC. FLU (30 mg/m 2 per day) was administered on days -8 to -3, rabbit ATG (Thymoglobuline ® , Genzyme, 2.5 mg/kg per day) was used on days -7 and -6. Low-dose total body irradiation (TBI) (3 Gy, with testis shielding) was performed on day -1 only for HSCT from an unrelated donor. The HSCT donor needs to be satisfied with more than 7/8 HLA-matching (HLA-A, B, C, DRB1) from a related or unrelated donor. HLA alleles were confirmed using molecular typing by sequence-based typing. In terms of sources, bone marrow was initially recommended. Tacrolimus and short-term methotrexate (days 1, 3, 6, and 11) were used for graft-versus-host disease (GVHD) prophylaxis. Tacrolimus was continued until 1 year after transplantation, and terminated if GVHD symptoms were absent.
Engraftment was defined as achievement of a neutrophil count of more than 500/mm 3 for three consecutive days. Chimerism analyses of T cells from peripheral blood and whole bone marrow specimens were performed by fluorescence in situ hybridization or short tandem repeat testing, depending on sex disparity between patients and donors.
In this study, the conventional 3 + 3 design was implemented, where the sequential assessment of the primary endpoint was conducted for each cohort. Thus, the planned sample size for this study was 6 or 9. The primary endpoint was event-free survival after 100 days of transplantation. Events were defined as graft failure and death from any cause. The secondary endpoints were engraftment at day 30, transplantation-related mortality before day 100, infectious events before week 8, GVHD, and recovery of the NADPH-oxidase function. This study was approved by the institutional review board (#1170), and registered in UMIN-CTR (http://www.umin.ac.jp/ctr/index.htm) number UMIN000022688.
Study enrollment was initiated in May 2015, and as five of six subjects in the first and second cohort completed the trial without any event at day 100, this pilot trial was successfully terminated in June 2016 without enrolling three additional patients. The detailed clinical characteristics and outcomes are shown in Table 1 . The disorders of all the patients were diagnosed at the genetic level. The median age of the patients was 9.5 years (range: 2-18 years). All cases had previous histories of CGD-related complications. Two patients had active colitis and were under treatment with steroids, and one patient had pulmonary infection and perianal abscess.
All patients underwent unrelated bone marrow transplantation (BMT), three from HLA-matched donors, and three from one-locus mismatched donors. Four of six cases had high-risk features [10] for HSCT. Based on results of the test-dose study, BU was reduced to a median of 63% (range: 50-73%) of the standard dose (Fig. 1a) . A median of cumulative AUC for actual BU administration was 45.9 mg/ L × h (range: 38.7-52.0) (Fig. 1b) .
All cases achieved neutrophil engraftment after a median of 18 days. Engraftment kinetics are shown in Fig. 2 . One patient (UPN 6) developed secondary graft failure at 2 months from BMT; he is currently being prepared for a second transplantation. The remaining five patients had sustained myeloid donor chimerism with >90% of NADPHoxidase activity at the last analysis, including four patients with follow-up periods of longer than 1 year from BMT.
Acute GVHD of grade III developed in one case (UPN 1), leading to chronic GVHD with bronchiolitis obliterans; this patient was still receiving steroid therapy at the last follow-up. Two cases (UPN 3 and 5) had grade I GVHD; they responded favorably to steroids that could be discontinued at the last follow-up.
Virus reactivation was detected in two cases, with CMV (n = 1) and EBV (n = 1), but no symptoms were observed; CMV was promptly removed by ganciclovir, and no therapy was required for EBV. One case (UPN 3) had mild sinusoidal obstruction syndrome, but it resolved promptly with administration of recombinant thrombomodulin alpha. Other non-hematologic adverse events more severe than grade 3 were not observed.
We prospectively confirmed that the targeted BU-based RIC followed by BMT from an unrelated donor was safe and worthwhile to further verify the effectiveness for CGD. Previous efforts to reduce intensity of conditioning regimens to avoid treatment-related toxicity and late complications were complicated by a high rate of graft failure and insufficient chimerism, and often required donor lymphocyte infusion or a second transplantation [3] . In our cohort, five of six cases (83.3%) achieved complete and sustained engraftment. One patient (UPN 6) whose BU exposures did not reach target range developed secondary graft failure, although his bone marrow fortunately had recovered autologously without severe complications. The graft failure should be associated with a one-locus mismatch in the hostversus-graft direction. Furthermore, the result is in line with the previous EBMT study [8] , which also demonstrated that all (36 of 36) cases with BU exposure of 45-65 mg/L × h achieved sustained myeloid engraftment, whereas two of eight cases with lower AUC developed graft failure. Oshrine et al. [11] reported that even with a similar conditioning regimen consisting of FLU, BU, and alemtuzumab, a lower BU AUC failed to achieve sufficient engraftment. Another study [12] showed that an AUC of 30-34 mg/L × h was associated with a substantial incidence of graft failure (31% of cases). A retrospective study showed that a treosulfanbased conditioning regimen could provide excellent overall survival of 91.4% for 70 CGD cases, but 12% of the cases developed secondary graft failure [13] . Considering this evidence, BU is an optimal agent to obtain solid engraftment for CGD, but further reduction to less than 45 mg/L × h would be difficult.
In vivo T-cell depletion with serotherapy is an important component of the conditioning regime to reduce risk of GVHD and achieve engraftment. The previous EBMT study [8] used alemtuzumab as an alternative for HSCT from unrelated donors, but unfortunately it is not approved for HSCT in Japan. Thus, we added low-dose irradiation with 3 Gy that can assist sustained engraftment, as reported for other non-malignant diseases [14] . Of course, even if it were a low dose, irradiation therapy could cause second malignancies. However, to keep the engraftment rates under the unrelated donor setting, we chose to add low-dose TBI.
In our cohort, one patient had grade III acute GVHD that resulted in development of chronic GVHD, although he received BMT from an HLA-matched unrelated donor. An increase in ATG dose potentially leads to a risk of infectious complications. Further optimization to control GVHD, such as post-transplant cyclophosphamide [15] , should be considered.
This study was a pilot study to confirm safety and minimum efficacy of RIC with targeted BU for CGD. Our results should be interpreted carefully. The number of cases was small and the follow-up period was not sufficiently long. Late complications, such as gonadal dysfunction or dental development, have yet to be assessed in a larger cohort with a longer duration of follow-up.
In conclusion, our prospective study demonstrated that BMT from unrelated donors for CGD using targeted BU conditioning provided acceptable engraftment and toxicity rates. We are planning to conduct a further prospective study at a larger scale to confirm the results.
Author contributions M. Kato is the principal investigator and takes primary responsibility for the paper, designed this study, interpreted 
